Skip to main content

Table 1 Classification of Participants demographic and clinical diagnosis based on age group

From: Immunohistochemical expression of PAX-8 in Sudanese patients diagnosed with malignant female reproductive tract tumors

  Age group no. (%) Total no. 60 P value
40—49 years 50—59 years 60—69 years 70—79 years
Residence of patient
 Central Sudan 2 (10.5) 12 (63.2) 4 (21.1) 1 (5.3) 19 (31.7) 0.550
 East Sudan 1 (16.7) 5 (83.3) 0 (0.0) 0 (0.0) 6 (10.0)
 West Sudan 6 (22.2) 10 (37.0) 9 (33.3) 2 (7.4) 27 (45.0)
 North Sudan 2 (25.0) 3 (37.5) 3 (37.5) 0 (0.0) 8 (13.3)
Site of cancer
 Cervix 10 (19.6) 25 (49.0) 13 (25.5) 3 (5.9) 51 (85.0) 0.885
 Endometrium 1 (20.0) 3 (60.0) 1 (20.0) 0 (0.0) 5 (8.3)
 Ovary 0 (0.0) 2 (40.0) 2 (40.0) 0 (0.0) 4 (6.7)
Cancer histological type
 SCC 9 (20.0) 22 (48.9) 13 (28.9) 1 (2.2) 45 (75.0) 0.330
 Adenocarcinoma 2 (13.0) 8 (53.3) 3 (20.0) 2 (13.3) 15 (25.0)
FIGO staging
 Stage 1 0 (0.0) 2 (66.7) 1 (33.3) 0 (0.0) 3 (5.0) 0.279
 Stage 2A 1 (16.7) 2 (33.3) 3 (50.0) 0 (0.0) 6 (10.0)
 Stage 2B 5 (35.7) 7 (50.0) 2 (14.3) 0 (0.0) 14 (23.3)
 Stage 3A 1 (12.5) 4 (50.0) 3 (37.5) 0 (0.0) 8 (13.3)
 Stage 3B 2 (11.8) 11 (64.7) 2 (11.8) 2 (11.8) 17 (28.3)
 Stage 4A 0 (0.0) 0 (0.0) 2 (66.7) 1 (33.3) 3 (5.0)
 Stage 4B 2 (22.2) 4 (44.4) 3 (33.3) 0 (0.0) 9 (15.0)
Histopathological cancer grades
 Well differentiated SCC 2 (16.7) 5 (41.7) 5 (41.7) 0 (0.0) 12 (20.0) 0.633
 Poorly differentiated SCC 3 (15.0) 10 (50.0) 6 (30.0) 1 (5.0) 20 (33.3)
 Moderately differentiated SCC 4 (30.8) 7 (53.8) 2 (15.4) 0 (0.0) 13 (21.7)
 Endometrium adenocarcinoma 1 (9.1) 6 (54.5) 2 (18.2) 2 (18.2) 11 (18.3)
 Endocervical adenocarcinoma 1 (100) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7)
 Metastatic adenocarcinoma 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0) 2 (3.3)
 Ovarian mucinous cyst adenocarcinoma 0 (0.0) 1 (100) 0 (0.0) 0 (0.0) 1 (1.7)
  1. SCC Squamous Cell Carcinoma